JPRN-UMIN000026925
Completed
未知
Combination therapy of immuno checkpoint inhibitors and radiosensitization treatment for metastatic melanoma - Immuno-radiosensitization treatment for metastatic melanoma
Kochi University, Kochi Medical School0 sites5 target enrollmentApril 10, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kochi University, Kochi Medical School
- Enrollment
- 5
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Unable to secure infusion route of drugs by using ultrasound or CT 2\) Determined to have high risk for bleeding by principalinvestigator or sub\-investigators 3\) Determined to have high risk for infection by principalinvestigator or sub\-investigators 4\) Determined to be inappropriate for this trial.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
Active, not recruiting
Phase 1
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-000058-24-NLErasmus MC Cancer Institute390
Recruiting
Phase 4
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.NSCLC and head and neck cancerrenal-cell cancerSolid or hematological tumors for which Nivolumab or Pembrolizumab monotherapy have an EMA approved indication. This includes (but is not limited to) melanomaVarious forms of cancer for which Nivolumab or Pembrolizumab monotherapy are prescribed as treatment10027656NL-OMON54425Erasmus MC, Universitair Medisch Centrum Rotterdam390
Not yet recruiting
Not Applicable
Immune checkpoint inhibitor therapy for advanced, recurrent or metastatic non-small cell lung cancer with low or negative PD-L1 expression.JPRN-UMIN000050723Kobe University200
Completed
Not Applicable
Combined therapy with immune-suppressive drug in children with immunoglobulin resistant Kawasaki diseaseKawasaki diseaseJPRN-UMIN000032096Dokkyo medical university52